GlassScriptPhysician profile
Amy C Byler
NPI 1891005377
$6,234.12
in general payments reported to CMS, 2019-2025
22 companies · $2,844 in 2025
The $2,844 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.00 · 2023: $1,150 · 2024: $2,165 · 2025: $2,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,908 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,908.00 |
| Education | $251.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,932.48 | 2023-2025 | |
| Amgen INC. | $1,132.34 | 2023-2025 | Otezla, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $605.22 | 2023-2025 | |
| Janssen Biotech, INC. | $567.82 | 2023-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $436.02 | 2023-2025 | Saphnelo |
| Ucb, INC. | $310.51 | 2024-2025 | Bimzelx, Cimzia |
| Fresenius Kabi USA, LLC | $240.53 | 2023-2025 | Idacio |
| Organon LLC | $170.91 | 2023-2025 | Hadlima, Renflexis |
| Lilly USA, LLC | $101.55 | 2023-2025 | Taltz, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.54 | 2023-2025 | Ofev, Spevigo |
| Pfizer INC. | $84.75 | 2024-2025 | |
| Bioventus LLC | $83.79 | 2025 | Durolane, Xcell |
| Aspira Women'S Health INC | $75.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $74.47 | 2025 | Orencia |
| Genzyme Corporation | $71.42 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $69.52 | 2023-2025 | |
| Sandoz INC. | $63.99 | 2023-2024 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $27.75 | 2025 | Acthar |
| Celltrion USA INC. | $24.14 | 2023 | Yuflyma |
| Ani Pharmaceuticals, INC. | $22.68 | 2025 | Purified Cortrophin Gel |
| Invivyd INC | $20.00 | 2025 | Pemgarda |
| Kyowa Kirin, INC. | $18.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Byler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.